JP2015020982A - Lycium fruit extract-containing oral solution, solubilizer and solubilization method - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide an oral solution which can stabilize lycium fruit extract and Vitamin B1s, hardly generate a sediment even when stored for a long period of time, and is excellent in feel of ingestion, while being clear.SOLUTION: An oral solution contains lycium fruit extract, Vitamin B1s, polyvinylpyrrolidone, and propylene glycol. The oral solution contains 300-800 mg of polyvinylpyrrolidone and 250-3000 mg of propylene glycol to 1000 mg of lycium fruit extract in terms of herbal medicine, and has pH of 2.3-3.5.

Description

  The present invention relates to a kokushi-derived extract-containing internal liquid that is stable and does not cause precipitation while having a good feeling of dosing.

  Kokushi (Lycii fructus) has effects of recovery from fatigue, tonicity, blood circulation promotion and visual acuity recovery, and is used as a herbal medicine. However, Kukosi extract is apt to be turbid in a liquid composition, and precipitates are generated particularly at low pH when stored for a long period of time. Therefore, measures for improving stability are necessary.

  On the other hand, vitamins B1 are a group of vitamins that are widely formulated in oral liquids for nourishing toughness and recovery from fatigue. However, the stability of long-term storage is poor at high pH. Therefore, when vitamin B1 is blended in an internal liquid, it is desirable to reduce the pH of the internal liquid.

  Therefore, when trying to add sorghum extract and vitamin B1 to the oral solution at the same time, the sorghum extract tends to precipitate when the pH is lowered to stabilize the vitamin B1, and when the pH is increased to prevent precipitation of the sorghum extract, the vitamin B1 is The problem of destabilization arises.

  As described above, various prescriptions for internal medicines containing sorghum extract and vitamin B1 having stability opposite to pH have been tried. It is known to emulsify or solubilize with various surfactants or solubilizers to prevent precipitation of wolfberry extract. For example, a technique of adding polyvinylpyrrolidone (Polyvinylpyrrolidone, PVP, povidone, Povidone) is known.

  Patent Document 1 discloses an internal liquid that does not cause precipitation by containing a sorghum-derived extract, vitamin B1, and PVP, but has a liquid pH of 4.5 and close to neutrality. Further, Patent Document 2 discloses an example in which good dosing feeling can be obtained by containing kokushi, vitamin B1, and PVP, and adjusting the pH to 3.5, but the stability of kokushi extract is disclosed. Is not mentioned.

  Moreover, propylene glycol (propylene glycol, PG) is known as an additive for internal liquids containing crude drugs, and Patent Document 3 discloses that PG is added together with PVP as a technique for preventing precipitation. Yes. However, the amounts of PVP and PG added in the technique disclosed in Patent Document 3 are both large, and there is no mention of herbal extracts. Moreover, in patent document 4, although PVP and PG are added to the internal use liquid containing a licorice etc. and vitamin B1, there is no description about the case where a crude drug is kokushi.

  Furthermore, PVP and PG have an unpleasant flavor, and if they contain a certain amount or more in the internal liquid, they have the property of deteriorating the ingestion of the internal liquid, so that the flavor is masked by the addition of a sweetener, etc. However, the effect was not sufficient.

Japanese Patent No. 4742289 JP 2001-213964 A Japanese Patent No. 4071212 JP 2007-153833 A

  When vitamin B1 is blended with an oral solution containing kukosi extract, it is stabilized at pH 3.5 or lower, and becomes unstable when pH 3.5 is exceeded. However, as described above, the kokushi extract tends to be turbid in the liquid composition, and precipitates are generated particularly at low pH when stored for a long period of time. In an internal use liquid as a product, since the visual appeal and appearance are important factors, it is required to be clear and not precipitate even after long-term storage.

  Accordingly, an object of the present invention is to provide a liquid preparation that can stabilize sorghum extract and vitamin B1 and is clear and resistant to precipitation even when stored for a long period of time, and has an excellent feeling of administration. To do.

  As a result of intensive studies, the present inventors have formulated a specific amount of PVP and a specific amount of PG as solubilizers into a liquid preparation containing sorghum extract and vitamin B1 at a pH of 3.5 or lower. The present inventors have found that it is stable and does not cause precipitation, and that the feeling of dosing is not impaired, and the present invention has been completed based on this finding.

That is, the present invention is as follows.
(1) An oral solution containing wolfberry extract, vitamin B1 class, polyvinyl pyrrolidone and propylene glycol, containing 300 to 800 mg of polyvinyl pyrrolidone and 250 to 3000 mg of propylene glycol with respect to 1000 mg of wolfberry extract converted to a crude drug, and pH 2 An internal solution that is 3 to 3.5.
(2) The internal use liquid preparation as described in (1) which contains 300-600 mg of polyvinylpyrrolidone with respect to 1000 mg of Kukosi extract converted into a crude drug.
(3) The internal liquid preparation according to (1) or (2), wherein 1 to 25 mg of vitamin B1 is contained with respect to 1000 mg of Kukosi extract converted into a crude drug.
(4) The internal liquid preparation according to any one of (1) to (3), wherein the vitamin B1 is at least one selected from the group consisting of thiamine, thiamine nitrate, thiamine hydrochloride, and fursultiamine.
(5) 0.2 to 6.7% by mass of Kukosi extract, 0.001 to 0.08% by mass of vitamin B1, 0.3 to 3.0% by mass of polyvinylpyrrolidone and 0.25 to 0.5% in terms of herbal medicine The internal use liquid preparation of any one of (1)-(4) containing 10 mass% propylene glycol.
(6) The internal use liquid preparation according to any one of (1) to (5), further comprising a jutei extract.
(7) In the manufacture of an oral liquid preparation containing kukosi extract and vitamin B1 and having a pH of 2.3 to 3.5, 300 to 800 mg of polyvinylpyrrolidone and 250 to 250 propylene glycol are used with respect to 1000 mg of kukoshi extract converted into a crude drug. A method for solubilizing kokushi extract to which 3000 mg is added.
(8) A solubilizer that is added to an oral solution having a pH of 2.3 to 3.5, and contains 300 to 800 mg of polyvinylpyrrolidone and 1000 to 800 mg of polyvinylpyrrolidone and 1000 mg converted to a crude drug. A solubilizer containing 250-3000 mg of propylene glycol.

  The internal liquid preparation of the present invention is formulated with a specific amount of PVP and a specific amount of PG as a solubilizer in an internal liquid preparation containing sorghum extract and vitamin B1, and even if the pH is 3.5 or lower, It is a liquid preparation that does not cause precipitation of wolfberry extract, can be stored for a long period of time, and further has an unpleasant feeling of taking PVP derived. Moreover, the internal use liquid agent of this invention is excellent in stability of vitamin B1 class by not producing the deposit of a wolfberry extract by making pH into 2.3 or more, and making pH into 3.5 or less.

  The internal liquid preparation of the present invention is an internal liquid preparation containing wolfberry extract, vitamin B1 class, polyvinylpyrrolidone and propylene glycol, and contains 300 to 800 mg of polyvinylpyrrolidone and 250 to 3000 mg of propylene glycol with respect to 1000 mg of wolfberry extract converted to a crude drug. And pH 2.3-3.5.

  The internal liquid preparation may contain other herbal extracts such as, for example, Ligustrum lucidum aiton extract, carrot (Ginseng radix) extract, ogi (Astragali radix) extract, oyster (Polygonati rhizoma) extract, or chestnut Extract, Giant (Rehmanniae Radix) extract, Toki (Angelicae radix) extract, Cai (Cinnamomi cortico pi) extract, Ceramus cerevisia corp extract, Epimedi erce citrus extract ) Extract, Muirapuama (Ptychopetalum olacoides) extract, Jikoppi (Lycil cortex) extract and Codonopsis (Codonopsitis radix) include extract. From the viewpoint of flavor, medicinal effect and formulation design, it is preferable to add a jotishi extract.

  The content of the crude drug extract in the internal use liquid preparation is preferably 0.3 to 10% by mass, more preferably 0.9 to 10% by mass in terms of crude drug equivalent. When the content of the herbal extract is 0.3% by mass or more, the effect and efficacy of the herbal medicine are easily expressed, and when it is 10% by mass or less, the stability of vitamin B1 is easily secured. is there.

  The content of the wolfberry extract in the oral liquid is preferably 0.2 to 6.7% by mass in terms of herbal medicine, more preferably 0.5 to 6.7% by mass, and still more preferably 1 to 6.7% by mass. . By setting the content of Kukosi extract to 0.2% by mass or more in terms of herbal medicine, it becomes easy to express the effects and efficacy of the herbal medicine, and by making it 6.7% by mass or less, it is particularly effective in formulation design. .

  In the case where the internal liquid preparation contains a jutei extract, the content of the jutei extract in the internal liquid preparation is preferably 0.1 to 3.4% by mass, more preferably 0.25 to 3.4% by mass in terms of herbal medicine. More preferably, it is 0.5 to 3.4% by mass. By making the content of the jotyi extract 0.1% by mass or more, the effect and efficacy of the herbal medicine can be easily expressed, and by making it 3.4% by mass or less, it is particularly effective in the formulation design.

  The production of the crude drug extract is carried out by a usual method, and the production of the extract is carried out by a usual method, for example, a method of extracting from a crude drug raw material at an appropriate temperature (low temperature or heating) using an extraction solvent. The extraction solvent can be appropriately selected depending on the crude drug, but preferably water, a hydrophilic solvent (especially ethanol) and a mixed solvent thereof are used.

  As the extract in the present invention, a liquid extract can be used as it is, and it can also be used as a diluted product of water or the like, a concentrate of a liquid extract, or a dried product of a liquid extract. That is, the extract in the present invention includes any of a dry extract, a soft extract, a flow extract, a tincture and the like.

  Vitamin B1 includes vitamin B1 and its derivatives. Examples of vitamin B1 include thiamine, thiamine salts and thiamine esters, and other thiamine derivatives. Specifically, for example, thiamine, thiamine nitrate, thiamine hydrochloride, fursultiamine, bisbenchamine, benfotiamine, thiamine disulfide, dicetiamine, thiamine propyl disulfide, thiamine hydroxyethyl tetrahydrofurfuryl disulfide, thiamine-8- (methyl -6-acetyldihydrothiooctate) disulfide and thiamineethyl disulfide. Among these, the present invention is particularly effective for improving the stability of thiamine, thiamine hydrochloride, thiamine nitrate and fursultiamine.

  The content of vitamin B1 in the oral solution is preferably 1 to 25 mg with respect to 1000 mg of wolfberry extract converted into a crude drug, and more preferably 5 to 12 mg from the viewpoint of the flavor of the vitamin B1 containing oral fluid.

  The content of vitamin B1 in the internal solution is preferably 0.001 to 0.08% by mass, and more preferably 0.005 to 0.04% by mass from the viewpoint of the flavor of the internal solution containing vitamin B1.

  The content of polyvinylpyrrolidone in the internal use liquid preparation is 300 to 800 mg, preferably 300 to 600 mg, more preferably 400 to 600 mg, with respect to 1000 mg of wolfberry extract converted into a crude drug. When the content of polyvinyl pyrrolidone is less than 300 mg with respect to 1000 mg of Kukosi extract converted into a crude drug, it is difficult to prevent precipitation or suspension that occurs over time during long-term storage. Moreover, when it exceeds 800 mg, the unpleasant flavor of a solubilizer appears.

  The content of polyvinylpyrrolidone in the internal liquid preparation is preferably 0.3 to 3.0% by mass, more preferably 0.3 to 2% by mass, and still more preferably 0.4 to 2% by mass. By setting the content of polyvinylpyrrolidone to 0.3% by mass or more, precipitation or suspension that occurs over time during long-term storage can be prevented, and by setting it to 3.0% by mass or less, a solubilizer Can suppress unpleasant flavor.

  By containing propylene glycol together with polyvinylpyrrolidone in the internal solution, the precipitate can be solubilized more effectively, and the stability of the internal solution is improved. The content of propylene glycol in the internal use liquid preparation is 250 to 3000 mg, preferably 500 to 2000 mg, more preferably 500 to 1000 mg, with respect to 1000 mg of wolfberry extract converted into a crude drug. When the content of propylene glycol is less than 250 mg with respect to 1000 mg of Kukosi extract converted into a crude drug, it is difficult to prevent precipitation or suspension that occurs over time during long-term storage. Moreover, when it exceeds 3000 mg, the unpleasant flavor of a solubilizer will appear.

  The content of propylene glycol in the internal solution is preferably 0.25 to 10% by mass, more preferably 0.5 to 6.7% by mass, and still more preferably 0.5 to 3.4% by mass. By setting the content of propylene glycol to 0.25% by mass or more, precipitation or suspension that occurs over time during long-term storage can be prevented. Can be suppressed.

  The mass ratio of polyvinylpyrrolidone and propylene glycol in the internal use liquid preparation is preferably 1: 0.3 to 10 and more preferably 1: 0.6 to 7 as the former: the latter. By adopting this ratio, the effect of preventing precipitation or suspension occurring over time is exhibited.

  The pH (pH at 25 ° C.) of the internal solution is 2.3 to 3.5, preferably 2.5 to 3.0, more preferably 2.5 to 2.8. When pH exceeds 3.5, vitamin B1 will become unstable. Moreover, precipitation will arise that pH is less than 2.3.

  The pH of the internal solution can be adjusted by blending a pH adjuster. The pH adjuster is not particularly limited and may be appropriately selected depending on the intended purpose. For example, hydrochloric acid, dilute hydrochloric acid, citric acid hydrate, sodium citrate, glycine, succinic acid, acetic acid, tartaric acid, D-tartaric acid , Sodium hydroxide, potassium hydroxide, magnesium hydroxide, lactic acid, calcium lactate, glacial acetic acid, monosodium fumarate, propionic acid, maleic acid, anhydrous citric acid, DL-malic acid, aspartic acid, glutamic acid, adipic acid, glucone Examples include acids, fumaric acid, boric acid, valeric acid, butyric acid, isobutyric acid, methylbutyric acid and sodium bicarbonate. Among these, dilute hydrochloric acid, acetic acid, butyric acid, and sodium hydroxide are preferable because the flavor of the aqueous oral solution composition is good. Said pH adjuster can be used individually by 1 type or in combination of 2 or more types.

  The internal liquid preparation may contain an optional component other than the above as long as the effects of the present invention are not impaired. Examples of the optional components include various vitamins other than vitamin B1 and other physiologically active ingredients, sweeteners, thickeners, solubilizers, preservatives (preservatives), stabilizers, fruit juices, flavors and pigments. Is mentioned. The addition amount of these optional components can be blended in a normal amount as long as the effects of the present invention are not hindered.

  Vitamins include vitamins and their derivatives. Examples of vitamins include vitamin A or derivatives thereof (retinol, retinol palmitate, etc.), vitamin B or derivatives thereof (vitamin B2 such as riboflavin sodium phosphate, vitamin B6 such as pyridoxine hydrochloride, vitamin B12, and nicotinamide. Vitamin B5 such as calcium pantothenate), vitamin C or a derivative thereof (ascorbic acid etc.), vitamin D or a derivative thereof, vitamin E or a derivative thereof (tocopherol, tocopherol acetate, etc.).

  Examples of other physiologically active ingredients include nicotinamide, caffeine, royal jelly, carnitine chloride, taurine, γ-aminobutyric acid, glucosamine, hyaluronic acid and capsaicin.

  The sweetener is not particularly limited and may be appropriately selected depending on the intended purpose. For example, sucrose, liquid sugar, fructose, fructose glucose liquid, glucose fructose liquid sugar, reduced maltose water candy, brown sugar, high fructose Liquid sugar, glucose, powdered reduced maltose water candy, water candy, high glucose water candy, lactose, sucrose, purified sucrose, purified sucrose spherical granules, honey, purified honey, simple syrup, erythritol, xylitol, D-sorbitol, D-sorbitol Solution, maltitol, maltitol solution, maltose, D-mannitol, aspartame, acesulfame potassium, amacha extract, licorice extract, saccharin, saccharin sodium, sucralose, stevia extract, neotame, thaumatin, glycine, glycerin, glycyrrhizinate Potassium, dinatrine glycyrrhizinate Sodium glycyrrhizinate tribasic include monoammonium glycyrrhizinate and licorice. Said sweetener can be used individually by 1 type or in combination of 2 or more types.

  The thickener is not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include natural water-soluble polymers such as carrageenan, gellan gum, pullulan and gum arabic; polyvinyl alcohol, methylcellulose, carboxymethylcellulose and hydroxypropyl. Examples include synthetic water-soluble polymers such as cellulose. By containing a thickener, the stability of each component in the liquid is improved.

  Examples of the solubilizer include surfactants such as polyoxyethylene hydrogenated castor oil and sucrose fatty acid ester, polyhydric alcohols and lower alcohols such as ethanol.

  The preservative (preservative) is not particularly limited and may be appropriately selected depending on the intended purpose. For example, benzoic acid, sodium benzoate, ethanol, sodium edetate, dry sodium sulfite, agar, dl-camphor, Citric acid hydrate, sodium citrate, glycerin, salicylic acid, sodium salicylate, phenyl salicylate, dibutylhydroxytoluene, D-sorbitol, sorbic acid, potassium sorbate, sodium dehydroacetate, sucrose, honey, isobutyl paraoxybenzoate, paraoxybenzoic acid Examples include isopropyl acid, ethyl paraoxybenzoate, butyl paraoxybenzoate, propyl paraoxybenzoate, methyl paraoxybenzoate, l-menthol and eucalyptus oil. These preservatives can be used alone or in combination of two or more.

  The stabilizer is not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include nicotinamide, sodium riboflavin phosphate, L-ascorbate stearate, L-ascorbate sodium, L- Sodium aspartate, aminoethylsulfonic acid, DL-alanine, sodium bisulfite, sodium sulfite, L-arginine, sodium alginate, propylene glycol alginate, albumin, benzoic acid, sodium benzoate, sulfur, inositol, ethanol, calcium edetate Sodium, sodium edetate, erythorbic acid, sodium ersorbate, calcium chloride, sodium chloride, magnesium chloride, cysteine hydrochloride, cacao butter, fructose, carboxyvinyl polymer, cal Loin calcium, carmellose sodium, hydrous silicon dioxide, dry sodium sulfite, dry aluminum hydroxide gel, dry aluminum hydroxide gel, dry sodium carbonate, xanthan gum, xylitol, calcium citrate, glycerin, glycerin fatty acid ester, disodium glycyrrhizinate, Light anhydrous silicic acid, crystalline cellulose, sodium acetate, sodium salicylate, phenyl salicylate, β-cyclodextrin, dibutylhydroxytoluene, sucrose fatty acid ester, calcium hydroxide, purified gelatin, purified soy lecithin, purified sucrose, cetanol, gelatin, sorbitan Fatty acid ester, sorbitan sesquioleate, D-sorbitol, D-sorbitol solution, soybean oil unsaponifiable matter, dextran, natural vitamin E, tocopherol, d-δ-tocopherol, tocopherol acetate, lactose, concentrated glycerin, sucrose, ethyl paraoxybenzoate, butyl paraoxybenzoate, methyl paraoxybenzoate, calcium pantothenate, microcrystalline cellulose, hydroxypropylcellulose, pyrosulfite Sodium, butylhydroxyanisole, glucose, monosodium fumarate, bentonite, propyl gallate, partially neutralized polyacrylic acid, polyoxyethylene hydrogenated castor oil, polyoxyethylene polyoxypropylene glycol, polysorbate, polyvinyl alcohol, polyvinyl alcohol Dibutyl ether mixture, macrogol, maltose, D-mannitol, anhydrous sodium pyrophosphate, sodium metaphosphate, methylcellulose, l Menthol, aluminum monostearate, glyceryl monostearate, medicinal carbon, sodium lauryl sulfate and ovalbumin. These stabilizers can be used alone or in combination of two or more.

  There is no restriction | limiting in particular in the preparation method of an internal use liquid agent, A well-known method can be used suitably. For example, it can be produced according to the Japanese Pharmacy Law General Rules for Preparations.

  The method for solubilizing wolfberry extract according to the present invention comprises blending wolfberry extract and vitamin B1 and, in the manufacture of an oral liquid having a pH of 3.5 or less, 300 to 800 mg of polyvinylpyrrolidone and propylene with respect to 1000 mg of wolfberry extract converted to a crude drug. 250 to 3000 mg of glycol is added.

  In the method for solubilizing wolfberry extract of the present invention, the content of polyvinylpyrrolidone is preferably 300 to 800 mg, more preferably 400 to 600 mg, with respect to 1000 mg of wolfberry extract converted to a crude drug.

  In the method for solubilizing wolfberry extract of the present invention, the pH of the internal solution (pH at 25 ° C.) can be adjusted by adding a pH adjuster as appropriate. For example, it can be adjusted by adding an aqueous solution containing a pH adjusting agent. Preferably it is 2.5-3.0, More preferably, it is 2.5-2.8.

  Further, the solubilizer of the present invention is a solubilizer that is added to an oral solution having a pH of 3.5 or less, and is obtained by adding polyvinylpyrrolidone to 1000 mg of Kukosi extract converted to a crude drug. 300 to 800 mg and 250 to 3000 mg of propylene glycol are added.

  In the solubilizer of the present invention, the content of polyvinylpyrrolidone is preferably 300 to 800 mg, more preferably 400 to 600 mg, with respect to 1000 mg of wolfberry extract converted into a crude drug.

  In the solubilizer of the present invention, the pH of the internal solution (pH at 25 ° C.) can be adjusted by appropriately adding a pH adjuster. For example, it can be adjusted by adding an aqueous solution containing a pH adjusting agent. Preferably it is 2.5-3.0, More preferably, it is 2.5-2.8.

  EXAMPLES Hereinafter, the present invention will be described in more detail with reference to examples, but the present invention is not limited to these examples. PVP is an abbreviation for polyvinylpyrrolidone and PG is an abbreviation for propylene glycol.

1. Analysis on solubility (Reference Examples 1 to 8)
In the formulation shown in Table 1, Kukosi extract crude drug equivalent 1000 mg, Jyoti extract crude drug equivalent 200 mg, thiamine nitrate 10 mg, riboflavin phosphate sodium 5 mg, PVP 400 mg, PG 500 mg are dissolved in purified water, and 2 mol / L water Reference Examples 1 to 8 were prepared so that the pH was adjusted with a sodium oxide solution and the total amount was 50 mL. As a result of observing with naked eyes the precipitation and turbidity of this preparation immediately after preparation (during production), it was transparent.

  In addition, the formulation was filled in a brown glass bottle and stored at 70 ° C. after sealing, and the result of examining the occurrence of precipitation and turbidity with the naked eye and the residual rate of vitamin B1 are shown in Table 1. Vitamin B1 is stable when the residual rate is 70% or more. In Table 1, “−” is clear and no precipitation or turbidity occurs, and “+” indicates that precipitation or turbidity occurs.

  As shown in Table 1, it was found that precipitation occurred when the pH of the oral solution was 3.5 or less. On the other hand, when pH exceeded 3.5, it was confirmed that stability of vitamin B1 falls.

(Reference Example 9)
A total amount of 50 mL of the preparation was prepared by removing the jotyi extract from the prescription in Reference Example 1.

(Reference Example 10)
A total amount of 50 mL of the preparation was prepared using the prescription of Reference Example 1 except for the kokushi extract.

  The occurrence of precipitation and turbidity immediately after preparation of the preparations of Reference Example 9 and Reference Example 10 adjusted to pH 2.7 (during production) was observed with the naked eye. The results are shown in Table 2. In Table 2, “−” is clear and no precipitation or turbidity occurs, and “+” indicates that precipitation or turbidity occurs.

  As shown in Table 2, Reference Example 10, which is a formulation not containing a jotyi extract, did not cause precipitation at pH 2.7, whereas Reference Example 9, which was a formulation not containing a kokushi extract, caused precipitation. From this result, it was found that the cause of precipitation caused by low pH was derived from Kukosi extract.

2. Analysis of the effect of the solubilizer As in Reference Example 1, by using the formulation shown in Table 3, using polyvinyl pyrrolidone (popidone K30, PVP) and propylene glycol (PG) as the solubilizer, the total amount was 50 mL. Examples 1, 2 and Comparative Examples 1-4 were prepared.

  With respect to this preparation, the occurrence of precipitation and turbidity immediately after preparation (during production) was observed with the naked eye. In addition, Table 3 shows the results of filling the preparation into a brown glass bottle, storing it at 70 ° C. after sealing, and examining the occurrence of precipitation and turbidity with the naked eye, and the residual ratio of vitamin B1.

  In Table 3, “−” is clear and no precipitation or turbidity occurs, “±” indicates that slight precipitation or turbidity occurs, and “+” indicates that precipitation or turbidity occurs. At the time of manufacture, Examples 1 and 2 and Comparative Examples 1 to 4 were all “−”.

  As shown in Table 3, Examples 1 and 2 in which PVP and PG were used in combination were clear and did not cause precipitation or turbidity. Therefore, it was found that the combination of PVP and PG can solubilize the precipitate more effectively. It was. In contrast, in Comparative Examples 1 to 4 using either PVP or PG, the occurrence of precipitation and turbidity could not be sufficiently suppressed.

3. Study on Addition Amount of Solubilizing Agent In the same manner as in Example 1, Examples 1-5 and Comparative Examples 5-11 were prepared so that the total amount would be 50 mL according to the formulation shown in Table 4 using 1100 mg of Kukosi extract crude drug equivalent amount. Was prepared.

  With respect to this preparation, the occurrence of precipitation and turbidity immediately after preparation (during production) was observed with the naked eye. Further, the preparation was filled in a brown glass bottle and stored at 70 ° C. after sealing, and the result of examination of the occurrence of precipitation and turbidity with the naked eye and the storage rate at 70 ° C. or 40 ° C. were examined for the residual ratio of vitamin B1. The results are shown in Table 4. In Table 4, “−” is clear and there is no precipitation and turbidity, “±” is no precipitation but there is slight turbidity, “+” is a small amount of precipitation but no turbidity, “++” is a small amount of turbidity Precipitation and slightly turbidity, “++” indicates precipitation and turbidity.

  As shown in Table 4, by containing 300 mg or more of PVP and 250 mg or more of PG with respect to 1000 mg of Kukosi extract converted into a crude drug, the precipitate is solubilized at a pH of 3.5 or less, and a clear preparation is obtained. I found out that

4). Confirmation of Presence of Precipitation in Low pH Range Examples 6 to 9 were prepared in the same manner as in Example 5 so that the total amount was 50 mL according to the formulation shown in Table 5.

  With respect to this preparation, the occurrence of precipitation and turbidity immediately after preparation (during production) was observed with the naked eye. The results are shown in Table 5. In Table 5, “-” indicates clear and no occurrence of precipitation and turbidity.

  As shown in Table 5, by containing 300 mg or more of PVP and 250 mg or more of PG in the preparation with respect to 1000 mg of Kukosi extract converted into a crude drug, the precipitate is solubilized and clarified in a low pH range of pH 3.0 or less. It was found that a simple formulation could be obtained.

5. Analysis on Vitamin B1 Formulation pH Dependence, Formulation Appearance, and Ingestion Example 10-18 and Comparative Examples 12-22 were prepared according to the formulation shown in Table 6 or Table 7 so that the total amount was 50 mL.

  With respect to this preparation, the occurrence of precipitation and turbidity immediately after preparation (during production) was observed with the naked eye. Tables 6 and 7 show the results obtained by filling the preparation into a brown glass bottle and storing at 70 ° C., and examining the occurrence of precipitation and turbidity with the naked eye, and the results of examining the residual ratio of vitamin B1s stored at 70 ° C. Shown in

  In Table 6, “−” is clear and no precipitation or turbidity occurs, “±” indicates slight precipitation or turbidity, “+” indicates a small amount of precipitation or turbidity, “++” indicates medium amount precipitation or turbidity Turbidity is recognized, “++++” indicates that a large amount of precipitation or turbidity is observed.

About this formulation, the sensory test was implemented by two testers, respectively, and the ingestion was evaluated. The evaluation of the feeling of dosing was based on the following evaluation criteria, and was evaluated by a four-point score evaluation of 1 to 4 points. The results are shown in Table 6.
4 points: feels unpleasant taste strongly 3 points: feels unpleasant taste 2 points: feels slightly unpleasant taste 1 point: does not feel unpleasant taste

  As shown in Tables 6 and 7, it was found that the stability of vitamin B1s was not dependent on the amount of excipients, but decreased depending on the storage temperature and pH. In addition, Example 5-1 containing 800 mg of PVP and not containing PG with respect to 1000 mg of Kukosi extract converted into a crude drug has a poor feeling of taking, whereas Example 5-2 contains 800 mg of PVP and contains PG. It was found that No. 5-3 and No. 5-3 have good dosing feeling, and the feeling of taking is improved by containing PG together with PVP.

  It was also found that the stability of vitamin B1 was secured by setting the pH of the preparation to 3.5 or less. Further, as shown in Table 7, since Comparative Example 22 having a pH of 2.2 caused precipitation, it was found that precipitation of wolfberry extract was not caused by setting the pH to 2.3 or more.

6). Formulation Example (Formulation Example 1)
Kukosi soft extract 275 mg (herbal equivalent 1100 mg), Jotei soft extract 55 mg (herbal equivalent 220 mg), thiamine nitrate 10 mg, riboflavin phosphate sodium 5 mg, pyridoxine hydrochloride 10 mg, nicotinamide 25 mg, anhydrous caffeine 50 mg, PVP 400 mg, PG 0.5 g, citric acid hydrate 269 mg, fructose 10 g, sodium benzoate 28 mg and propyl gallate 3 mg were dissolved in purified water, and the pH was adjusted to 3.0 with 2 mol / L sodium hydroxide solution. A total volume of 50 mL of internal solution was prepared.

(Prescription example 2)
Kukosi soft extract 250mg (herbal medicine equivalent 1000mg), thiamine nitrate 10mg, PVP 400mg and PG 0.5g are dissolved in purified water, pH is adjusted to 2.6 with 2mol / L sodium hydroxide solution, total volume 50mL An internal solution was prepared.

(Prescription Examples 3 to 7)
In the same manner as in Formulation Example 1 or Formulation Example 2, each component shown in Table 8 was stirred and dissolved in purified water, adjusted to the pH shown in Table 8 with a 2 mol / L sodium hydroxide solution, and a total volume of 50 mL of internal solution was prepared. Obtained.

Claims (8)

  An oral solution containing wolfberry extract, vitamins B1, polyvinyl pyrrolidone and propylene glycol, containing 300 to 800 mg of polyvinyl pyrrolidone and 250 to 3000 mg of propylene glycol with respect to 1000 mg of wolfberry extract converted into a crude drug, and having a pH of 2.3 to 2.3 An internal solution that is 3.5.   The internal use liquid agent of Claim 1 which contains 300-600 mg of polyvinylpyrrolidone with respect to 1000 mg of wolfberry extract converted into a crude drug.   The internal use liquid agent of Claim 1 or 2 which contains 1-25 mg of vitamin B1 types with respect to 1000 mg of Kukosi extract converted into a crude drug.   Vitamin B1 is at least 1 sort (s) chosen from the group which consists of thiamine, thiamine nitrate, thiamine hydrochloride, and fursultiamine, The internal use liquid agent of any one of Claims 1-3.   0.2 to 6.7% by weight of Kokushi extract, 0.001 to 0.08% by weight of vitamin B1, 0.3 to 3.0% by weight of polyvinyl pyrrolidone and 0.25 to 10% by weight in terms of crude drug The internal use liquid agent of any one of Claims 1-4 containing the propylene glycol of.   Furthermore, the internal use liquid agent of any one of Claims 1-5 containing a jotyi extract.   In the manufacture of oral liquids containing Kukosi extract and vitamin B1 and having a pH of 2.3 to 3.5, 300 to 800 mg of polyvinylpyrrolidone and 250 to 3000 mg of propylene glycol are added to 1000 mg of Kukosi extract converted to herbal medicine. To solubilize kokushi extract.   It is a solubilizer which is added to an internal liquid preparation having a pH of 2.3 to 3.5, and contains 300 to 800 mg of polyvinylpyrrolidone and 250 to 3000 mg with respect to 1000 mg of Kukosi extract converted to a crude drug. A solubilizer containing propylene glycol.